Coya Therapeutics, Inc.
COYA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $0 | $0 | $0 |
| - Cash | $0 | $30 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | – | -$30 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 2,078.4% | -36.6% | 13,111.3% | – |
| Gross Profit | $0 | $0 | -$0 | -$0 |
| % Margin | 99.8% | 95.8% | -1,921.9% | -99,154.1% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -59.2% | -3,721% | -2,974.2% | -208,681.1% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -59.4% | -3,725.2% | -2,833.4% | -149,373.8% |
| EPS Diluted | -0.13 | -0.36 | -0.44 | -0.18 |
| % Growth | 63.9% | 18.2% | -144.4% | – |
| Operating Cash Flow | -$0 | -$0 | -$3 | -$0 |
| Capital Expenditures | $0 | -$0 | $0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$3 | -$0 |